Webinar: Choosing Your Next Treatment: What FL Patients Should Know

Dr. Mitchell Smith, FLF’s CMO guides an important discussion with world-renowned clinical lymphoma expert Prof Kim Linton (University of Manchester), and FL survivor and entrepreneur Ari Akerstein. Together, the panel discusses and shares insights on what matters most to doctors and patients when navigating their next treatment options. Key Topics include: How do I navigate treatment choices, while managing potential risks? How does my doctor balance effectiveness, side effects, and quality of life? How may early decisions impact future treatment possibilities? When to explore new therapies or clinical trials? What are the emotional and psychological aspects of transitioning between treatments? What are the key questions to ask my healthcare team? If you're unsure about any of the terms and treatments discussed, please visit our glossary: https://www.theflf.org/your-support-hub/ You can register your interest in our webinars to be notified when you can register here: https://www.theflf.org/your-support-h... If you've found our videos helpful, please consider donating to the Follicular Lymphoma Foundation. Your support helps us accelerate research towards a cure for FL and improve the lives of those affected: https://www.theflf.org/donate/ [Disclaimer: This video is intended for educational and disease awareness purposes only and the information presented and discussed does not constitute medical advice. The presentations contain data and information regarding not yet approved treatments and/or off-label use which are not to be construed as recommendations. Please consult with your healthcare provider for medical advice.] You can find out more about the PETReA Plus Study mention on this webinar here: https://www.theflf.org/our-research/o... Our funding partners for PETReA Plus Study are: Blood Cancer UK & Joyce and Norman Freed Charitable Trust. Acknowledgement - This webinar series is supported by sponsorship from AstraZeneca, Genmab, AbbVie, Ipsen and Incyte. All of the above have had no influence on, control of, nor input into the development or performance of the webinar series.